Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 225, Issue 3, Pages 470-475Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiab373
Keywords
inflammation; biomarker; immune response; flare; hepatitis B; HBV; plasma; cytokines; chemokines
Categories
Funding
- Gilead Research Scholars in Liver Disease Grant
- Toronto Centre for Liver Disease
- Canada Foundation for Innovation, John R. Evans Leaders Fund [35756]
Ask authors/readers for more resources
Liver damage in hepatitis B is immune driven and correlates with inflammatory markers in patient serum. Different stages of the disease have distinct inflammatory profiles, with more inflammatory markers detected in chronic patients and elevated concentrations of cytotoxic effectors in chronic hepatitis B patients with liver damage.
Liver damage in hepatitis B is immune driven and correlates with inflammatory markers in patient serum. There is no comparison of these markers to determine if inflammatory profiles are distinct to different types of liver damage across patients at different stages of disease. We measured 25 inflammatory markers in patients with acute hepatitis B and chronic hepatitis B with hepatitis B e antigen seroconversion and chronic patients stopping nucleoside analogue therapy. Myeloid markers dominated the inflammatory profile in all stages of hepatitis B. More inflammatory markers were detectable in chronic patients, including elevated concentrations of cytotoxic effectors Fas ligand, TRAIL, and TNF-alpha. The myeloid marker CD163 dominated the inflammatory profile across liver damage associated with different stages of hepatitis B virus infection. While profiles overlapped substantially, chemokines and cytotoxic effector molecules were elevated in chronic hepatitis B patients with liver damage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available